

BREATHING NEW LIFE INTO INHALATION R&D

The latest medical and business news from Inhalation Sciences

Welcome to a regular roundup of business and medical news from ISAB. Find out how we're breathing new life into inhalation R&D.

1

INHALABLE VACCINES & THE FIGHT AGAINST TB: DDL2017 HIGHLIGHTS

It's the largest, most important event in Europe's pulmonary drug delivery calendar—this year there were more visitors, and research posters, than ever at the Drug Delivery to the Lungs (DDL) Conference, Edinburgh, December 6-8. What were the highlights?

READ MORE: <http://www.inhalation.se/en/inhalable-vaccines-the-fight-against-tb-ddl2017-highlights/>

ISAB'S IN-VITRO TECHNOLOGY XPOSEALI® GRANTED PATENT IN CHINA

Inhalation Sciences' patent application for XposeALI®, the company's unique, proprietary module for aerosol exposure of cells, has been approved in China. The product patent, which includes the design of the product, applies until the end of 2033. Inhalation Sciences' products are protected by a total of 6 patent families.

READ MORE: <http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseld=2743176>

ISAB RESEARCH CONTRACT IN FORMAMP PROJECT ON ANTIBIOTIC RESISTANCE EXTENDED BY 1.2 MSEK.

Antibiotic resistance is one of the most pressing health concerns on the planet. The EU research project FORMAMP is exploring ways of using Antimicrobial Peptides (AMPs) combined with other nanoformulation strategies, to prevent it. Inhalation Sciences has been contracted to carry out an additional series of studies for the project, extending its role and research revenues.

READ MORE: <http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseld=2726862>

ASTRAZENECA REPORT FINDS PRECISEINHALE 'REDUCES THE RISK' OF FAILURE WHEN DEVELOPING INHALED DRUGS

New research released by Astra Zeneca at the Association of Inhalation Toxicologists (AIT) Conference in Copenhagen, Denmark, October 26-27 shows that PreciseInhale can reduce risk and speed up drug development: "dose levels could be selected with confidence before moving into the toxicology study, reducing the risk...inherent with this class of drugs."

READ MORE AT: <http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseld=2711691>

To see this Newsletter as a complete PDF go to <http://www.inhalation.se/en/news/> or
<http://www.inhalation.se/nyheter/>